Drugs / 14C-OPS-2071
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02440633 | May → Aug 2015 | enteritis | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 14C-OPS-2071 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02440633 ↗ |
| Route | Oral | “Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.” NCT02440633 ↗ |